|本期目录/Table of Contents|

[1]刘 璐,赖 倩.雾化吸入布地奈德治疗AECOPD合并2型糖尿病患者疗效及对肺通气功能和糖代谢的影响[J].中华肺部疾病杂志,2021,(04):427-430.[doi:10.3877/cma.j.issn.1674-6902.2021.04.005]
　Liu Lu,Lai Qian..Therapeutic effects of aerosol inhalation of budesonide on acute exacerbation of chronic obstructive pulmonary disease with type 2 diabetes mellitus and the influence on pulmonary ventilation function and glucose metabolism indicators[J].,2021,(04):427-430.[doi:10.3877/cma.j.issn.1674-6902.2021.04.005]
点击复制

雾化吸入布地奈德治疗AECOPD合并2型糖尿病患者疗效及对肺通气功能和糖代谢的影响(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年04期
页码:
427-430
栏目:
论著
出版日期:
2021-08-20

文章信息/Info

Title:
Therapeutic effects of aerosol inhalation of budesonide on acute exacerbation of chronic obstructive pulmonary disease with type 2 diabetes mellitus and the influence on pulmonary ventilation function and glucose metabolism indicators
作者:
刘 璐; 赖 倩
610000 成都,四川大学华西医院呼吸与危重症医学科
Author(s):
Liu Lu;  Lai Qian.
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610000, China
关键词:
布地奈德;  肺疾病; 慢性阻塞性;  2型糖尿病;  肺通气功能;  糖代谢
Keywords:
Budesonide;  Chronic obstructive pulmonary disease;  Type 2 diabetes mellitus;  Pulmonary ventilation function;  Glucose metabolism
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2021.04.005
摘要:
目的 分析雾化吸入布地奈德治疗慢性阻塞性肺疾病急性加重(AECOPD)合并2型糖尿病(T2DM)患者疗效及对肺通气功能和糖代谢指标的影响。方法 选择四川大学华西医院 2019年1月至2020年5月诊治的120例AECOPD合并T2DM患者作为对象,根据非随机临床同期对照研究及患者自愿原则分为对照组58例和观察组62例,其中对照组给予低剂量布地奈德治疗,观察组给予高剂量布地奈德治疗。比较两组患者治疗前后肺通气功能、糖代谢指标和炎性因子水平变化,并评估疗效和安全性。结果 两组患者治疗有效率比较无显著差异(P>0.05); 与治疗前比,两组患者治疗后肺通气功能指标均显著升高,但观察组较对照组升高更为显著(P<0.05); 两组患者之间及其治疗前后糖代谢指标均无显著差异(P>0.05); 与治疗前比,两组患者治疗后炎症因子水平均显著降低,但观察组较对照组降低更为显著(P<0.05); 两组不良反应发生率比较无统计学意义(P>0.05)。结论 布地奈德雾化吸入治疗AECOPD合并T2DM安全有效,对糖代谢指标无明显影响,但高剂量的布地奈德对于患者肺通气功能和炎症水平改善效果更好。
Abstract:
Objective To study the therapeutic effects of aerosol inhalation of budesonide on acute exacerbation of chronic obstructive pulmonary disease(AECOPD)with type 2 diabetes mellitus(T2DM)and the influence on pulmonary ventilation function and glucose metabolism indicators. Methods Between January 2019 and May 2020, 120 patients with AECOPD and T2DM were selected as the subjects. According to the non-randomized clinical concurrent controlled study and patient voluntary principle, they were divided into control group 58 cases and observation group 62 cases. Control Group was treated with low-dose budesonide, while observation group was treated with high-dose budesonide. Changes in pulmonary ventilation function, glucose metabolism indicators and inflammatory factors before and after treatment were compared between the two groups. The efficacy and safety were evaluated. Results There was no significant difference in the response rate between the two groups(P>0.05). After treatment, the pulmonary ventilation function indexes significantly increased, and the increases were greater in observation group than in control group(P<0.05). No significant differences were observed in glucose metabolism indexes between the two groups or in the same group before and after treatment(P>0.05). After treatment, the levels of inflammatory factors decreased significantly, and the decreases were greater in observation group than in control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Aerosol inhalation of budesonide is safe and effective in the treatment of AECOPD with T2DM, without significant effect on glucose metabolism. However, high-dose budesonide can better improve pulmonary ventilation and relieve inflammation.

参考文献/References:

1 张小娥, 张彩莲. 慢性阻塞性肺疾病流行病学及疾病经济负担研究进展[J]. 中国慢性病预防与控制, 2017, 25(6): 472-476.
2 张 颖, 林英翔. 慢性阻塞性肺疾病急性加重住院患者一年及长期死亡风险因素分析[J]. 中华结核和呼吸杂志, 2019, 042(012): 895-900.
3 潘建新, 任 臻, 王凤梅, 等. 合并2型糖尿病的慢性阻塞性肺疾病急性加重期患者的临床特点及防治对策[J]. 实用医学杂志, 2015, 31(11): 1810-1812.
4 敖冬梅, 孙程程, 赖 倩, 等. 慢性阻塞性肺疾病合并糖尿病患者临床特点及相关因素分析[J]. 中国慢性病预防与控制, 2017, 25(02): 85-87.
5 邱 勤, 文富强. 布地奈德与糖皮质激素对老年AECOPD合并Ⅱ型糖尿病患者的疗效对比研究[J]. 西部医学, 2016, 28(004): 479-482.
6 中华中医药学会内科分会肺系病专业委员会. 慢性阻塞性肺疾病中医诊疗指南(2011版)[J]. 中医杂志, 2012, 53(1): 80-84.
7 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J]. 中华内分泌代谢杂志, 2014, 30(10): 26-89.
8 陈美玉, 汤 彦. 慢性阻塞性肺疾病疗效评估指标的现状与评价[J]. 中国实用内科杂志, 2006, 26(13): 1023-1025.
9 吴金斌, 郑若洋, 欧嘉文. 定量检测降钙素原的方法学评价[J]. 检验医学与临床, 2015, 12(6): 780-780.
10 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
11 严晓青, 张 艺, 严 军, 等. 慢性阻塞性肺疾病急性发作期合并糖尿病病人血流变指标及凝血纤溶功能的变化[J]. 蚌埠医学院学报, 2018, 43(3): 388-390.
12 孙婉璐, 陈亚红. 慢性阻塞性肺疾病急性加重糖皮质激素应用现状与依据[J]. 中国实用内科杂志, 2018, 38(5): 446-450.
13 刘 琴. 糖皮质激素在AECOPD治疗中的研究进展[J]. 海南医学, 2019, 30(1): 102-105.
14 张 蕊, 陈 碧, 李元芹, 等. 雾化吸入不同剂量布地奈德在治疗慢性阻塞性肺病急性加重期的疗效[J]. 实用医学杂志, 2019, 35(24): 3827-3831.
15 符 琴, 王 成. 慢性阻塞性肺病急性加重期患者治疗前后肺功能通气指标变化特征[J]. 中国老年学杂志, 2015, 35(8): 223-224.
16 黄大海, 武庆红, 郭 媛, 等. 大剂量布地奈德联合中药治疗慢性阻塞性肺疾病急性加重期临床观察[J]. 解放军医药杂志, 2016, 28(B10): 29-31.
17 蒋艳秋, 夏 阳, 袁 毅. 雾化吸入较大剂量布地奈德治疗COPD急性加重期的临床探究[J]. 中国急救医学, 2018, 38(0z1): 41.
18 徐 曼. 慢性阻塞性肺疾病急性加重合并2型糖尿病胰岛素抵抗的炎症及氧化应激机制探讨[D]. 安徽医科大学, 2018: 1-46.
19 于 红. 合并慢性阻塞性肺疾病的糖尿病患者短期应用糖皮质激素治疗后血糖升高的特点及胰岛素剂量调整方案[J]. 中国医药, 2015, 10(9): 1311-1315.

备注/Memo

备注/Memo:
通信作者: 刘 璐, Email: luluguangjie1989@163.com
更新日期/Last Update: 2021-08-20